Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication

Jae Woo Chung, Roxana G. Burciu, Edward Ofori, Priyank Shukla, Michael S. Okun, Christopher W. Hess, David E. Vaillancourt

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Objective A prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time. Methods Fifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for >12h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus. Results ON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p
Original languageEnglish (US)
Pages (from-to)417-421
Number of pages5
JournalNeuroImage: Clinical
StatePublished - 2017


  • dMRI
  • Parkinson's disease
  • Antiparkinsonian medication
  • Free-water
  • Free-water corrected fractional anisotropy


Dive into the research topics of 'Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication'. Together they form a unique fingerprint.

Cite this